FDA to Convene Advisory Panel on Expanding Compounding Pharmacy Access to Peptides

The U.S. Food and Drug Administration is set to convene an outside advisory panel to deliberate whether compounding pharmacies should be permitted to manufacture certain peptides, a decision that could dramatically reshape access to a class of drugs that has surged in popularity amid the GLP-1 weight loss medication boom. The move comes at a critical juncture as the agency faces mounting political, legal, and public pressure over the future of compounded versions of drugs like semaglutide and tirzepatide.

The scheduled advisory committee meeting marks a potentially pivotal moment in one of the most contentious pharmaceutical policy battles in recent years. Peptides — short chains of amino acids that serve as building blocks for proteins — have become central to modern medicine, most prominently through GLP-1 receptor agonists used to treat type 2 diabetes and obesity. The global market for GLP-1 drugs alone is projected to exceed $100 billion annually by the end of this decade, driven by blockbuster medications such as Ozempic, Wegovy, Mounjaro, and Zepbound. The explosive demand has created persistent supply challenges, and compounding pharmacies stepped in to fill the void by producing custom-made versions of these peptides at significantly lower cost — often between $100 and $400 per month compared to the roughly $1,000 to $1,350 list price for brand-name alternatives.

Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to produce copies of FDA-approved drugs when those drugs appear on the agency’s official shortage list. When the FDA determined in early 2025 that the semaglutide shortage had resolved, it triggered a legal and political firestorm. Compounding pharmacies and their advocates — including several members of Congress — argued that removing these drugs from the shortage list would abruptly cut off millions of patients who had come to rely on affordable compounded versions. Multiple lawsuits were filed challenging the FDA’s determination, and federal courts in some cases issued temporary restraining orders that allowed compounding to continue while litigation proceeded. The Outsourcing Facilities Association, which represents 503B compounding pharmacies that operate under stricter federal oversight, has been particularly vocal in arguing that their facilities meet rigorous quality standards and should be permitted to continue production. Meanwhile, Novo Nordisk and Eli Lilly have contended that compounded peptides pose serious safety risks, citing concerns about sterility, dosing accuracy, and the lack of the extensive clinical trials that their branded products underwent.

The advisory panel’s deliberations are also unfolding against a broader political backdrop. The Trump administration has signaled interest in lowering drug prices and expanding patient access, and several senior officials — including figures within the Department of Health and Human Services — have publicly expressed support for maintaining some pathway for compounded peptides. At the same time, the FDA faces the institutional challenge of balancing drug safety mandates with unprecedented public demand. An estimated 15 million or more Americans have used GLP-1 medications, and surveys indicate that a substantial portion of those users obtained their prescriptions through telehealth platforms connected to compounding pharmacies. The advisory panel is expected to weigh scientific evidence on the safety and efficacy of compounded peptides, the capacity of the regulated compounding sector to meet quality standards, and the public health implications of restricting access. While FDA advisory committee recommendations are non-binding, the agency follows their guidance in the vast majority of cases — historically adopting panel recommendations approximately 75 to 80 percent of the time.

What comes next will be closely watched by patients, physicians, pharmaceutical companies, compounding pharmacies, and lawmakers alike. If the panel recommends broader access, it could pave the way for a more permanent regulatory framework allowing compounded peptides even outside of shortage conditions — a development that would represent a significant shift in how the FDA treats complex biological products. If the panel recommends tighter restrictions, it could accelerate the legal battles already underway and intensify political pressure on the agency. A specific date for the advisory committee meeting has not yet been publicly announced, but stakeholders on all sides are already preparing testimony and position papers in anticipation of what could be one of the most consequential FDA advisory panel meetings in years.